Macitentan in the Young—Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

BACKGROUND: Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH, but data on...

Descripción completa

Detalles Bibliográficos
Autores principales: Albinni, Sulaima, Heno, Julian, Pavo, Imre, Kitzmueller, Erwin, Marx, Manfred, Michel-Behnke, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284929/
https://www.ncbi.nlm.nih.gov/pubmed/37269500
http://dx.doi.org/10.1007/s40272-023-00573-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284929/
https://www.ncbi.nlm.nih.gov/pubmed/37269500
http://dx.doi.org/10.1007/s40272-023-00573-y

Ejemplares similares